马凡综合征儿童及年轻成人的健康相关生活质量
本研究基于Pediatric Heart Network马凡试验的多中心队列,用PedsQL 4.0评估321例5-25岁马凡综合征患者的健康相关生活质量。儿童期躯体与心理社会领域评分低于健康常模,成人期心理社会评分高于常模;患者报告症状频率与神经发育障碍与较低生活质量相关,而治疗分组和躯体特征严重程度无关联。
要点
- 马凡综合征儿童和青少年躯体及心理社会生活质量低于健康常模。
- 患者报告症状越多,多个领域生活质量越差。
- 合并神经发育障碍的<18岁患者生活质量评分更低。
核心结论
- 马凡综合征儿童和青少年是健康相关生活质量受损的高风险人群。
- 患者报告的症状和神经发育障碍与较低生活质量相关,而治疗分组或马凡综合征相关躯体表现严重程度无关联。
研究设计与样本
- 多中心队列研究,纳入参与Pediatric Heart Network Marfan Trial的321例5-25岁马凡综合征患者。
- 使用PedsQL 4.0通用核心量表评估健康相关生活质量,并与健康人群常模比较。
- 采用一般线性模型评估治疗分组(阿替洛尔vs氯沙坦)、临床特征严重程度和患者报告症状数量对生活质量的影响。
主要发现
- 5-18岁马凡综合征儿童PedsQL平均评分在躯体领域(P≤.003)和心理社会领域(P<.001)低于健康常模。
- 19-25岁成人心理社会领域平均评分高于健康常模(P<.001)。
- 生活质量多个领域与患者报告症状频率呈负相关(r=0.30-0.38,P<.0001)。
- 18岁以下合并神经发育障碍(主要为学习障碍、注意缺陷/多动障碍)者PedsQL平均评分低5.5-7.4分(P<.04)。
- 多变量模型发现年龄、性别、患者报告症状和神经发育障碍是生活质量的独立预测因素。
关键数值与推荐
- 5-18岁马凡综合征患者躯体领域PedsQL评分低于健康常模,P≤.003。
- 5-18岁马凡综合征患者心理社会领域PedsQL评分低于健康常模,P<.001。
- 19-25岁马凡综合征患者心理社会领域PedsQL评分高于健康常模,P<.001。
- 生活质量多个领域与患者报告症状频率负相关,r=0.30-0.38,P<.0001。
- 18岁以下合并神经发育障碍者PedsQL评分低5.5-7.4分,P<.04。
临床怎么用
- 儿科医生应关注马凡综合征儿童和青少年的生活质量,尤其躯体与心理社会领域。
- 评估时应询问患者报告的症状频率,症状越多提示生活质量可能越差。
- 对合并神经发育障碍的马凡综合征患儿应加强生活质量监测与支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess health-related quality of life (HRQOL) in a large multicenter cohort of children and young adults with Marfan syndrome participating in the Pediatric Heart Network Marfan Trial. STUDY DESIGN: The Pediatric Quality of Life Inventory (PedsQL) 4.0 Generic Core Scales were administered to 321 subjects with Marfan syndrome (5-25 years). PedsQL scores were compared with healthy population norms. The impact of treatment arm (atenolol vs losartan), severity of clinical features, and number of patient-reported symptoms on HRQOL was assessed by general linear models. RESULTS: Mean PedsQL scores in children (5-18 years) with Marfan syndrome were lower than healthy population norms for physical (P ≤ .003) and psychosocial (P < .001) domains; mean psychosocial scores for adults (19-25 years) were greater than healthy norms (P < .001). HRQOL across multiple domains correlated inversely with frequency of patient-reported symptoms (r = 0.30-0.38, P < .0001). Those <18 years of age with neurodevelopmental disorders (mainly learning disability, attention-deficit/hyperactivity disorder) had lower mean PedsQL scores (5.5-7.4 lower, P < .04). A multivariable model found age, sex, patient-reported symptoms, and neurodevelopmental disorder to be independent predictors of HRQOL. There were no differences in HRQOL scores by treatment arm, aortic root z score, number of skeletal features, or presence of ectopia lentis. CONCLUSIONS: Children and adolescents with Marfan syndrome were at high risk for impaired HRQOL. Patient-reported symptoms and neurodevelopmental disorder, but not treatment arm or severity of Marfan syndrome-related physical findings, were associated with lower HRQOL.
引用
- Handisides JC, Hollenbeck-Pringle D, Uzark K, et al. Health-Related Quality of Life in Children and Young Adults with Marfan Syndrome. J Pediatr. 2018. PMID: 30270167. doi:10.1016/j.jpeds.2018.08.061
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。